Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Eigentler

Showing results (51-60 of 127) with videos related to

Pageof 13
Sort By:
Journal of the American Academy of Dermatology|April 25, 2009
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patientsFriedegund Meier, Emmanuella Guenova, Stephan Clasen, et al.
Plos One|January 5, 2024
Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapyFelix Peisen, Annika Gerken, Isabel Dahm, et al.
Neuro-Oncology Advances|December 11, 2020
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER studyTeresa Amaral, Heike Niessner, Tobias Sinnberg, et al.
Melanoma Research|July 16, 2008
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanomaAxel Hauschild, Uwe Trefzer, Claus Garbe, et al.
Cancers|April 26, 2020
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV MelanomaTeresa Amaral, Olivia Seeber, Edgar Mersi, et al.
European Journal of Radiology|March 15, 2016
CT imaging of bone and bone marrow infiltration in malignant melanoma--Challenges and limitations for clinical staging in comparison to 18FDG-PET/CTGeorg Bier, Vera Hoffmann, Christopher Kloth, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanomaAndreas Stefan Brendlin, Felix Peisen, Haidara Almansour, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 7, 2020
Maria-Ioanna Stefanou, Irina Gepfner-Tuma, Cornelia Brendle, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 10, 2019
Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapyMaria-Ioanna Stefanou, Irina Gepfner-Tuma, Cornelia Brendle, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 14, 2020
Dermatofluoroscopy diagnostics in different pigmented skin lesions: Strengths and weaknessesMaja Ann Hofmann, Ulrike Keim, Agata Jagoda, et al.
Pageof 13

Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
Journal of the American Academy of Dermatology|April 25, 2009
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patientsFriedegund Meier, Emmanuella Guenova, Stephan Clasen, et al.
Plos One|January 5, 2024
Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapyFelix Peisen, Annika Gerken, Isabel Dahm, et al.
Neuro-Oncology Advances|December 11, 2020
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER studyTeresa Amaral, Heike Niessner, Tobias Sinnberg, et al.
Melanoma Research|July 16, 2008
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanomaAxel Hauschild, Uwe Trefzer, Claus Garbe, et al.
Cancers|April 26, 2020
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV MelanomaTeresa Amaral, Olivia Seeber, Edgar Mersi, et al.
European Journal of Radiology|March 15, 2016
CT imaging of bone and bone marrow infiltration in malignant melanoma--Challenges and limitations for clinical staging in comparison to 18FDG-PET/CTGeorg Bier, Vera Hoffmann, Christopher Kloth, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanomaAndreas Stefan Brendlin, Felix Peisen, Haidara Almansour, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 7, 2020
Maria-Ioanna Stefanou, Irina Gepfner-Tuma, Cornelia Brendle, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 10, 2019
Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapyMaria-Ioanna Stefanou, Irina Gepfner-Tuma, Cornelia Brendle, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 14, 2020
Dermatofluoroscopy diagnostics in different pigmented skin lesions: Strengths and weaknessesMaja Ann Hofmann, Ulrike Keim, Agata Jagoda, et al.
Pageof 13